A detailed history of High Mark Wealth Management LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, High Mark Wealth Management LLC holds 30 shares of HALO stock, worth $1,869. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30
Holding current value
$1,869
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$37.81 - $52.4 $1,134 - $1,572
30 New
30 $1,000
Q3 2023

Oct 18, 2023

SELL
$36.46 - $44.03 $382,830 - $462,315
-10,500 Reduced 25.13%
31,290 $1.2 Million
Q4 2022

Feb 01, 2023

SELL
$40.06 - $59.44 $268,402 - $398,248
-6,700 Reduced 13.82%
41,790 $2.38 Million
Q3 2022

Oct 21, 2022

SELL
$38.53 - $51.78 $65,501 - $88,026
-1,700 Reduced 3.39%
48,490 $1.92 Million
Q2 2022

Jul 19, 2022

BUY
$37.35 - $48.3 $18,675 - $24,150
500 Added 1.01%
50,190 $2.21 Million
Q1 2022

Apr 25, 2022

SELL
$31.97 - $41.06 $92,713 - $119,074
-2,900 Reduced 5.51%
49,690 $1.98 Million
Q4 2021

Jan 20, 2022

SELL
$31.82 - $40.75 $23,896 - $30,603
-751 Reduced 1.41%
52,590 $2.12 Million
Q3 2021

Nov 01, 2021

SELL
$38.47 - $46.42 $4,462 - $5,384
-116 Reduced 0.22%
53,341 $2.17 Million
Q2 2021

Aug 02, 2021

BUY
$38.84 - $51.31 $417,335 - $551,325
10,745 Added 25.16%
53,457 $2.43 Million
Q1 2021

Apr 22, 2021

BUY
$39.51 - $51.45 $812,562 - $1.06 Million
20,566 Added 92.87%
42,712 $947,000
Q4 2020

Jan 27, 2021

SELL
$25.81 - $43.62 $138,573 - $234,195
-5,369 Reduced 19.51%
22,146 $946,000
Q3 2020

Oct 26, 2020

BUY
$25.74 - $29.63 $691,608 - $796,128
26,869 Added 4159.29%
27,515 $723,000
Q2 2020

Jul 22, 2020

BUY
$16.25 - $26.81 $10,497 - $17,319
646 New
646 $17,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.68B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track High Mark Wealth Management LLC Portfolio

Follow High Mark Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Mark Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Mark Wealth Management LLC with notifications on news.